Bayer’s FINEROD Study: Evaluating Finerenone in Real-World Settings

Bayer AG ((BAYRY)), Bayer Ag (UK) ((GB:0P6S)) announced an update on their ongoing clinical study.

Study Overview: Bayer AG is conducting an observational study titled ‘Finerenone Research of Outcomes and Drug Utilization’ (FINEROD) to evaluate the real-world use, safety, and effectiveness of finerenone in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) in Japan and the United States. The study aims to gather data on patient characteristics, kidney function, and other health conditions to better understand finerenone’s impact in routine clinical settings.

Intervention/Treatment: The study focuses on finerenone, a drug designed to block mineralocorticoid receptors, potentially reducing damage to kidneys, heart, and blood vessels in patients with CKD and T2D. Finerenone is administered in doses of 10 mg or 20 mg daily.

Study Design: This is a retrospective observational cohort study utilizing data from electronic health records and national claims in the US and Asia. It does not involve any specific allocation, intervention model, or masking, as it solely observes existing data without additional interventions.

Study Timeline: The study began on May 15, 2024, with an initial submission date of February 9, 2024. The latest update was submitted on July 29, 2025. These dates mark the study’s progress and updates, indicating ongoing data collection and analysis.

Market Implications: As Bayer continues to gather real-world data on finerenone, the study’s outcomes could influence investor sentiment and Bayer’s stock performance. Positive results may strengthen Bayer’s market position in the CKD and T2D treatment space, potentially impacting competitors focused on similar therapeutic areas.

The study is currently recruiting, with further details available on the ClinicalTrials portal.